Drugs and valvular heart disease.
Roth
Bryan L
BL
Department of Pharmacology, Schools of Medicine and Pharmacy, National Institute of Mental Health Psychoactive Drug Screening Program at the University of North Carolina, Chapel Hill, USA.
D000978:Antiparkinson Agents / Q000009:adverse effects; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000009:adverse effects*; D004873:Ergolines / Q000009:adverse effects*; D006349:Heart Valve Diseases / Q000139:chemically induced*; D006801:Humans; D010479:Pergolide / Q000009:adverse effects*; D044403:Receptor, Serotonin, 5-HT2B / Q000378:metabolism; D058826:Serotonin 5-HT2 Receptor Agonists; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000494:pharmacology
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D004873:Ergolines; D044403:Receptor, Serotonin, 5-HT2B; D058826:Serotonin 5-HT2 Receptor Agonists; D017366:Serotonin Receptor Agonists; D010479:Pergolide; D000077465:Cabergoline